GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HOOKIPA Pharma Inc (NAS:HOOK) » Definitions » Gross Margin %

HOOKIPA Pharma (HOOKIPA Pharma) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is HOOKIPA Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. HOOKIPA Pharma's Gross Profit for the three months ended in Mar. 2024 was $36.60 Mil. HOOKIPA Pharma's Revenue for the three months ended in Mar. 2024 was $36.60 Mil. Therefore, HOOKIPA Pharma's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for HOOKIPA Pharma's Gross Margin % or its related term are showing as below:


HOOK's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.74
* Ranked among companies with meaningful Gross Margin % only.

HOOKIPA Pharma had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for HOOKIPA Pharma was 0.00% per year.


HOOKIPA Pharma Gross Margin % Historical Data

The historical data trend for HOOKIPA Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HOOKIPA Pharma Gross Margin % Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial - - - - -

HOOKIPA Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of HOOKIPA Pharma's Gross Margin %

For the Biotechnology subindustry, HOOKIPA Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HOOKIPA Pharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Gross Margin % falls into.



HOOKIPA Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

HOOKIPA Pharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=20.1 / 20.129
=(Revenue - Cost of Goods Sold) / Revenue
=(20.129 - 0) / 20.129
=N/A %

HOOKIPA Pharma's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=36.6 / 36.599
=(Revenue - Cost of Goods Sold) / Revenue
=(36.599 - 0) / 36.599
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


HOOKIPA Pharma  (NAS:HOOK) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HOOKIPA Pharma had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


HOOKIPA Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of HOOKIPA Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


HOOKIPA Pharma (HOOKIPA Pharma) Business Description

Traded in Other Exchanges
N/A
Address
350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Executives
Reinhard Kandera director, officer: Chief Financial Officer C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Jorn Aldag director, officer: Chief Executive Officer C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Katia Schlienger officer: Chief Medical Officer 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Malte Peters director TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Timothy P. Reilly director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Igor Matushansky officer: Chief Medical Officer C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Sofinnova Capital Vi Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008
Christine D. Baker officer: Chief Business Officer C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Jean-charles Soria director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118
Anders Lilja officer: Sr. VP, Technical Development C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Klaus Orlinger officer: Sr. VP, Research C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Roman Necina officer: Chief Technology Officer C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Forbion Capital Fund Ii Cooperatief U.a. 10 percent owner C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016